![Mark Forman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Dr. Mark Forman was previously employed as a Chief Medical Officer by Ventyx Biosciences, Inc., a Chief Medical Officer by Passage Bio, Inc., a Vice President by ACADIA Pharmaceuticals, Inc., and an Executive Director by Translational Medicine Accelerator.
He received his undergraduate degree from Yale University, a doctorate degree from The Rockefeller University and a doctorate degree from Duke University.
Eerdere bekende functies van Mark Forman
| Bedrijven | Functie | Einde |
|---|---|---|
| VENTYX BIOSCIENCES, INC. | Hoofd Techniek/Wetenschap/O&O | 04-03-2026 |
| PASSAGE BIO, INC. | Hoofd Techniek/Wetenschap/O&O | 02-08-2024 |
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | 01-01-2021 |
Translational Medicine Accelerator | Directeur/Bestuurslid | - |
Opleiding van Mark Forman
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
48
Eerstegraads connecties
7
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 7 |
|---|---|
ACADIA Pharmaceuticals, Inc.
 ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Rockefeller University
 The Rockefeller University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Passage Bio, Inc.
 Passage Bio, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of monogenic central nervous system disorders | Health Technology |
Ventyx Biosciences, Inc.
 Ventyx Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops oral therapies for patients with autoimmune, inflammatory and neurodegenerative diseases | Health Technology |
Translational Medicine Accelerator |
